Global Markets Direct’s, ‘Hyper Pigmentation - Pipeline Review, H2 2014’, provides an overview of the Hyper Pigmentation’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Hyper Pigmentation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyper Pigmentation and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Hyper Pigmentation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyper Pigmentation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyper Pigmentation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyper Pigmentation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyper Pigmentation - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyper Pigmentation pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Hyper Pigmentation - Pipeline Review, H2 2014 Table of Contents Introduction 5 Global Markets Direct Report Coverage 5 Hyper Pigmentation Overview 6 Therapeutics Development 7 Pipeline Products for Hyper Pigmentation - Overview 7 Pipeline Products for Hyper Pigmentation - Comparative Analysis 8 Hyper Pigmentation - Therapeutics under Development by Companies 9 Hyper Pigmentation - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Hyper Pigmentation - Products under Development by Companies 13 Hyper Pigmentation - Companies Involved in Therapeutics Development 14 Kasiak Research Pvt. Ltd. 14 MediQuest Therapeutics, Inc. 15 RXi Pharmaceuticals Corporation 16 Hyper Pigmentation - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 MQX-054 - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 NPH-29 - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 Refaglo - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 TRY-26071 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 TRY-26077 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables
Number of Products under Development for Hyper Pigmentation, H2 2014 7 Number of Products under Development for Hyper Pigmentation - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Comparative Analysis by Unknown Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Hyper Pigmentation - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 14 Hyper Pigmentation - Pipeline by MediQuest Therapeutics, Inc., H2 2014 15 Hyper Pigmentation - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 16 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 23 Number of Products by Stage and Molecule Type, H2 2014 25
List of Figures
Number of Products under Development for Hyper Pigmentation, H2 2014 7 Number of Products under Development for Hyper Pigmentation - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Assessment by Monotherapy Products, H2 2014 17 Number of Products by Top 10 Targets, H2 2014 18 Number of Products by Stage and Top 10 Targets, H2 2014 19 Number of Products by Top 10 Mechanism of Actions, H2 2014 20 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21 Number of Products by Top 10 Routes of Administration, H2 2014 22 Number of Products by Stage and Top 10 Routes of Administration, H2 2014 23 Number of Products by Top 10 Molecule Types, H2 2014 24 Number of Products by Stage and Top 10 Molecule Types, H2 2014 25